Renier J. Brentjens, MD, PhD

home / authors / renier-j-brentjens-md-phd

Articles

CAR T Pioneers Describe Challenges Faced in Cancer

Renier J. Brentjens, MD, PhD;Manjusha Namuduri, MD

July 16th 2020

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

Dr. Brentjens Discusses the Future of CAR T-Cell Therapy

Renier J. Brentjens, MD, PhD

July 3rd 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the future of chimeric antigen receptor T-cell therapy.

Dr. Brentjens Discusses Targets for CAR T-Cell Therapy

Renier J. Brentjens, MD, PhD

May 8th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.

Dr. Brentjens on Managing Patients After CAR T-Cell Therapy

Renier J. Brentjens, MD, PhD

April 4th 2018

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses managing patients after treatment with chimeric antigen receptor (CAR) T-cell therapy.

Dr. Brentjens on CAR T-Cell Therapy Challenges

Renier J. Brentjens, MD, PhD

January 30th 2015

Renier Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, talks about the challenges of Chimeric Antigen Receptor (CAR) T-Cell therapies for the treatment of hematologic cancers.

Dr. Brentjens on the Potential Application of CAR-Modified T Cell Technology

Renier J. Brentjens, MD, PhD

April 24th 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the potential application of CAR-modified T cell technology.

Dr. Brentjens on Challenges of CAR-Modified T Cells

Renier J. Brentjens, MD, PhD

March 31st 2014

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the challenges associated with CAR-modified T cells.

Dr. Brentjens on Modifying T Cells in Hematologic Cancers

Renier J. Brentjens, MD, PhD

November 22nd 2013

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, explains how CAR-modified T cells can be used to treat hematologic cancers.

Dr. Brentjens on the Side Effects of CAR-Modified T Cells

Renier J. Brentjens, MD, PhD

September 4th 2013

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the side effects of chimeric antigen receptor (CAR)â€“modified T cells when used to treat B-cell malignancies.

Dr. Brentjens on Treatment With CAR-Modified T Cells

Renier J. Brentjens, MD, PhD

July 1st 2013

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the treatment of B-cell malignancies with chimeric antigen receptor(CAR)â€“modified T cells.